Kirk Keegan III MD, MPH
Senior Medical Director
Janssen Research and Development
Medical School: Georgetown University, Washington D.C.
Residency: University of California, Davis
Fellowship: Vanderbilt University Medical Center
Active Clinical Trials
FKD Therapies/Instiladrin
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Taris Biomedical-MIBC
A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects with Muscle-Invasive Urothelial Carcinoma of The Bladder Who are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who are Unfit for Radical Cystectomy